NCT05925452View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

NARecruitingINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

March 24, 2028

Study Completion Date

June 29, 2028

Conditions
Active Systemic Juvenile Idiopathic Arthritis
Interventions
DRUG

GenaKumab

GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w

Trial Locations (10)

100045

RECRUITING

Children's Hospital Affiliated to Capital Medical University, Beijing

201102

NOT_YET_RECRUITING

Affiliated Pediatric Hospital of Fudan University, Shanghai

210008

NOT_YET_RECRUITING

Children's Hospital Affiliated to Nanjing Medical University, Nanjing

215002

NOT_YET_RECRUITING

Children's Hospital of Soochow University, Suzhou

310016

NOT_YET_RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

325099

NOT_YET_RECRUITING

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

400015

NOT_YET_RECRUITING

Children's Hospital Affiliated to Chongqing Medical University, Chongqing

410323

NOT_YET_RECRUITING

Hunan Children's Hospital, Changsha

610073

NOT_YET_RECRUITING

Chengdu Women and Children's Central Hospital, Chengdu

710002

NOT_YET_RECRUITING

Xi'an Children's Hospital, Xi’an

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY